The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2- advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.
 
Nagi El Saghir
Honoraria - Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
(OPTIONAL) Uncompensated Relationships - Roche
 
Hamdy Azim
Honoraria - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Novartis; Roche
 
Yesim Eralp
Honoraria - Amgen; Amgen; AstraZeneca; BMS Turkey; Gilead Sciences
Consulting or Advisory Role - Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis
Research Funding - Novartis
Other Relationship - Novartis
 
Yoon Sim Yap
Honoraria - AstraZeneca; DKSH; Gilead Sciences; MSD; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly; MSD; Novartis; Pfizer
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; DKSH; MSD; Pfizer
 
Malwinder Sandhu
No Relationships to Disclose
 
Hikmat Abdel-Razeq
No Relationships to Disclose
 
Sudeep Gupta
Research Funding - Amgen (Inst); AstraZeneca (Inst); Celltrion (Inst); Intas (Inst); Johnson & Johnson (Inst); Novartis (Inst); Oncostem Diagnostics (Inst); Roche (Inst); Sanofi (Inst)
 
Elena Artamonova
No Relationships to Disclose
 
Julie Rihani
No Relationships to Disclose
 
Juan Carlos Mora Payan
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Yogesh Chattar
Employment - Novartis
 
Gary Sopher
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Melissa Gao
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis